Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 21 Lymphoma 13 Lung Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Urinary Bladder Neoplasms 5 Testicular Neoplasms 3 Prostatic Neoplasms 3 Melanoma 3 Urethral Neoplasms 2 Testicular Germ Cell Tumor 2 Teratoma 2 Lymphoma, Large-Cell, Anaplastic 2 Uterine Cervical Neoplasms 1 Skin Neoplasms 1 Seminoma 1 Ovarian Neoplasms 1 Ovarian Germ Cell Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1 Leukemia 1 Endodermal Sinus Tumor 1 Carcinoma, Embryonal 1 Adenocarcinoma of Lung 1

Interventions

Rituximab 66 Cyclophosphamide 46 Vincristine 40 Doxorubicin 40 Prednisone 35 Etoposide 19 Radiotherapy 14 Gemcitabine 13 Peripheral Blood Stem Cell Transplantation 12 Filgrastim 12 Cytarabine 12 Lenalidomide 11 Carmustine 10 VAP-cyclo protocol 9 Prednisolone 9 Oxaliplatin 9 Melphalan 9 Methotrexate 7 Ifosfamide 7 Mitoxantrone 6 Bleomycin 6 polatuzumab vedotin 5 R-CHOP protocol 4 Methylprednisolone 4 Injections 4 Granulocyte Colony-Stimulating Factor 4 Cyclosporine 4 Cisplatin 4 Carboplatin 4 pegfilgrastim 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Large B-Cell, Diffuse × Vinblastine × Clear all

NCT01148446 2010-06-22

ANZINTER3

Fondazione Italiana Linfomi - ETS

Phase 3 Completed

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡